MacroGenics (MGNX) Class Action Lawsuit Alert: Johnson Fistel Announces Shareholders with Substantial Losses Have the Opportunity to Lead the Action
Shareholder rights law firm Johnson Fistel, LLP announces that a class action lawsuit has commenced on behalf of investors of MacroGenics, Inc. (“MacroGenics”) (NASDAQ: MGNX).
CLASS PERIOD: March 7, 2024 to May 9, 2024
LEAD PLAINTIFF DEADLINE: September 24, 2024
DOCKET #: 24-CV-02184 (D. Maryland
ALLEGATIONS: False and/or misleading statements
Contact for More Information: James Baker, (619) 814-4471, jimb@johnsonfistel.com or fjohnson@johnsonfistel.com
According to the lawsuit, throughout the Class Period, defendants provided overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts related to early interim safety data results from the TAMARACK Phase 2 study. The claims arise on May 9, 2024, when MacroGenics presented interim updated safety and efficacy data for its cancer treatment study TAMARACK.
Investor Action Steps: Shareholders who incurred losses during the class period, have until September 24, 2024, to move the court to become a lead plaintiff in this action.A lead plaintiff will act on behalf of all other class members in directing the class-action lawsuit. The lead plaintiff can select a law firm of its choice to litigate the class-action lawsuit. An investor’s ability to share any potential future recovery of the class action lawsuit is not dependent upon serving as lead plaintiff.